Irving


IRVING, Texas and ABBOTT PARK, Illinois, June 16, 2011 - - Pivotal clinical trial will further assess drug candidate's effect on kidney function - Reata Pharmaceuticals, Inc.

IRVING, Texas and ABBOTT PARK, Illinois, November 20, 2010 - Reata Pharmaceuticals and Abbott (NYSE: ABT) today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug.
Older News
S M T W T F S
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
Copyright© 2011 The Gaea Times